JosephClaytonGatheJr.MDFACP FIDSA
Infectious Disease • Houston, TXHIV/AIDS Medicine
CEO Therapeutic Concepts
Dr. Gathe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4900 Fannin St
Houston, TX 77004Phone+1 713-526-9821Fax+1 713-526-0614
Education & Training
Baylor College of MedicineFellowship, Infectious Disease, 1985 - 1986- Baylor College of MedicineResidency, Internal Medicine, 1981 - 1984
- Baylor College of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1981 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- A Study to Compare Two Anti-HIV Drug Combinations Start of enrollment: 1999 Oct 01
- Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients Start of enrollment: 2005 Jun 01
- A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects Start of enrollment: 2010 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Efficacy and safety of two fixed doses of ibalizumab plus optimized background regimen in treatment-experienced HIV-positive individuals.Edwin DeJesus, William J Towner Jr, Joseph C Gathe, R Brandon Cash, Kaitlin Anstett
Journal of Acquired Immune Deficiency Syndromes. 2024-09-09 - 9 citationsEfficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study.Joseph Gathe, Robin L Hardwicke, Fernando Garcia, Steven Weinheimer, Stanley T. Lewis
Journal of Acquired Immune Deficiency Syndromes. 2021-04-01 - 1 citationsVitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy.Rustin D. Crutchley, David M. Jacobs, Joseph Gathe, Carl Mayberry, Nataliya Bulayeva
Current HIV Research. 2021-01-01
Press Mentions
BEWARE: COVID-19 Is STILL HERE and on the Rise…Once AgainJuly 21st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
